These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19182813)

  • 21. Clinical, biochemical and imaging methods of assessing osteoarthritis and clinical trials with agents claiming 'chondromodulating' activity.
    Theiler R; Ghosh P; Brooks P
    Osteoarthritis Cartilage; 1994 Mar; 2(1):1-23. PubMed ID: 11548220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for testing slow acting drugs in osteoarthritis.
    Lequesne M; Brandt K; Bellamy N; Moskowitz R; Menkes CJ; Pelletier JP; Altman R
    J Rheumatol Suppl; 1994 Sep; 41():65-71; discussion 72-3. PubMed ID: 7799389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years.
    Loef M; Kroon FPB; Bergstra SA; van der Pol JA; Lems WF; Kerstens PJSM; Allaart CF; Kloppenburg M
    Rheumatology (Oxford); 2018 Nov; 57(11):1917-1924. PubMed ID: 29471377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory arthritis in children with osteochondrodysplasias.
    Scuccimarri R; Azouz EM; Duffy KN; Fassier F; Duffy CM
    Ann Rheum Dis; 2000 Nov; 59(11):864-9. PubMed ID: 11053062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.
    Detert J; Klaus P; Listing J; Höhne-Zimmer V; Braun T; Wassenberg S; Rau R; Buttgereit F; Burmester GR
    Trials; 2014 Oct; 15():412. PubMed ID: 25348033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future therapeutics for osteoarthritis.
    Martel-Pelletier J; Wildi LM; Pelletier JP
    Bone; 2012 Aug; 51(2):297-311. PubMed ID: 22037003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease-modifying effects of TD-198946 on progressed osteoarthritis in a mouse model.
    Yano F; Ohba S; Hosaka Y; Saito T; Chung UI
    Ann Rheum Dis; 2014 Nov; 73(11):2062-4. PubMed ID: 25135252
    [No Abstract]   [Full Text] [Related]  

  • 28. The age of osteoarthritis.
    Birrell F; Felson D
    Age Ageing; 2009 Jan; 38(1):2-3. PubMed ID: 19054784
    [No Abstract]   [Full Text] [Related]  

  • 29. New horizons in osteoarthritis.
    Wenham CY; Conaghan PG
    Age Ageing; 2013 May; 42(3):272-8. PubMed ID: 23568255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is glucosamine worth taking for osteoarthritis?
    Drug Ther Bull; 2002 Nov; 40(11):81-3. PubMed ID: 12462851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights into osteoarthritis from MRI.
    Tan YK; Conaghan PG
    Int J Rheum Dis; 2012 Feb; 15(1):1-7. PubMed ID: 22324940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?
    Vignon EP; Moreland L
    Osteoarthritis Cartilage; 2004; 12 Suppl A():S61-2. PubMed ID: 14698645
    [No Abstract]   [Full Text] [Related]  

  • 33. Cellular senescence in osteoarthritis and anti-aging strategies.
    Hou A; Chen P; Tang H; Meng H; Cheng X; Wang Y; Zhang Y; Peng J
    Mech Ageing Dev; 2018 Oct; 175():83-87. PubMed ID: 30107185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-arthritic agents: progress and potential.
    Laev SS; Salakhutdinov NF
    Bioorg Med Chem; 2015 Jul; 23(13):3059-80. PubMed ID: 26014481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets.
    Pelletier JP; Martel-Pelletier J; Abramson SB
    Arthritis Rheum; 2001 Jun; 44(6):1237-47. PubMed ID: 11407681
    [No Abstract]   [Full Text] [Related]  

  • 36. Motion for debate: osteoarthritis clinical trials have not identified efficacious therapies because traditional imaging outcome measures are inadequate.
    Guermazi A; Roemer FW; Felson DT; Brandt KD
    Arthritis Rheum; 2013 Nov; 65(11):2748-58. PubMed ID: 23861096
    [No Abstract]   [Full Text] [Related]  

  • 37. Magnetic resonance imaging applications in early rheumatoid arthritis diagnosis and management.
    Troum OM; Pimienta O; Olech E
    Rheum Dis Clin North Am; 2012 May; 38(2):277-97. PubMed ID: 22819084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update: treatment of osteoarthritis.
    Chard J; Dieppe P
    Arthritis Rheum; 2002 Dec; 47(6):686-90. PubMed ID: 12522845
    [No Abstract]   [Full Text] [Related]  

  • 39. Osteoarthritis, imaging and guidance for approval of a structural "indication".
    Simon LS
    Osteoarthritis Cartilage; 2006; 14 Suppl A():A2-3. PubMed ID: 16678454
    [No Abstract]   [Full Text] [Related]  

  • 40. Imaging outcomes and their role in determining outcomes in osteoarthritis and rheumatoid arthritis.
    Hunter DJ; Conaghan PG
    Curr Opin Rheumatol; 2006 Mar; 18(2):157-62. PubMed ID: 16462521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.